Need professional-grade analysis? Visit stockanalysis.com
$16.48B
25.43
2,426
2.09%
Price Chart
Risk-Adjusted Performance
Shenyang Xingqi Pharmaceutical Co Ltd (300573) Price Performance
Shenyang Xingqi Pharmaceutical Co Ltd (300573) trades on SHE in CNY. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at CNY66.30, down 1.32% from the previous close.
Over the past year, 300573 has traded between a low of CNY49.11 and a high of CNY83.32. The stock has gained 32.1% over this period. It is currently 20.4% below its 52-week high.
Shenyang Xingqi Pharmaceutical Co Ltd has a market capitalization of $16.48B, with a price-to-earnings ratio of 25.43 and a dividend yield of 2.09%.
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, and dry eye medicines. It also engages in the technology development, technical consultation, and eye hospital businesses, as well as production and wholesale of pharmaceuticals. The company was founded in 1977 and is based in Shenyang, the People's Republic of China.
Compare Shenyang Xingqi Pharmaceutical Co Ltd
Side-by-side comparison against top Healthcare peers.
Company Info
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- SHE
- Currency
- CNY
- Country
- China
Financial Metrics
- Revenue (TTM)
- $2.41B
- EBITDA
- $868.01M
- Profit Margin
- 26.84%
- EPS (TTM)
- 2.63
- Book Value
- 7.57
Technical Indicators
- 52 Week High
- CN¥85.65
- 52 Week Low
- CN¥48.56
- 50 Day MA
- CN¥68.79
- 200 Day MA
- CN¥69.24
- Beta
- 0.49
Valuation
- Trailing P/E
- 25.43
- Forward P/E
- N/A
- Price/Sales
- 6.85
- Price/Book
- 9.00
- Enterprise Value
- $16.46B